CARLSMED, INC.
For the period ended Sep 30, 2025. Filed Nov 6, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2025 · Filed Nov 6, 2025
CARL$14.52-5.2%Stored close · as of Nov 6, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONDENSED BALANCE SHEETS
(in thousands, except for share and par value amounts)
(unaudited)
| September 30, 2025 | December 31, 2024 | |
|---|---|---|
| Assets | ||
| Current assets: | ||
| Cash and cash equivalents | $115,373 | $40,125 |
| Restricted cash | 100 | 100 |
| Accounts receivable, net of allowances of $1,601 and $1,239, as of September 30, 2025 and December 31, 2024, respectively | 11,296 | 6,766 |
| Inventory | 1,340 | 995 |
| Prepaid expenses and other current assets | 3,356 | 1,365 |
| Total current assets | 131,465 | 49,351 |
| Property and equipment, net | 1,187 | 260 |
| Operating lease right-of-use assets | 1,986 | 1,644 |
| Other assets | 225 | 569 |
| Total assets | $134,863 | $51,824 |
| Liabilities, Convertible Preferred Stock, and Stockholders’ Equity (Deficit) | ||
| Current liabilities: | ||
| Accounts payable | $2,672 | $2,412 |
| Accrued liabilities | 3,186 | 2,687 |
| Accrued compensation | 4,409 | 3,270 |
| Short-term operating lease liabilities | 661 | 449 |
| Total current liabilities | 10,928 | 8,818 |
| Long-term portion of term loan, net | 15,440 | 15,414 |
| Long-term operating lease liabilities | 1,513 | 1,317 |
| Warrant liabilities | 32 | 457 |
| Other long-term liabilities | 290 | 222 |
| Total liabilities | 28,203 | 26,228 |
| Commitments and contingencies (Note 9) | ||
| Series A convertible preferred stock, $0.00001 par value; zero and 4,902,814 shares authorized, issued, and outstanding, and zero and $13,767 liquidation preference as of September 30, 2025 and December 31, 2024, respectively | — | 13,578 |
| Series B convertible preferred stock, $0.00001 par value; zero and 4,393,481 shares authorized, zero and 4,335,051 shares issued and outstanding, and zero and $30,000 liquidation preference as of September 30, 2025 and December 31, 2024, respectively | — | 29,801 |
| Series C convertible preferred stock, $0.00001 par value; zero and 4,910,500 shares authorized, zero and 4,890,123 shares issued and outstanding, and zero and $52,500 liquidation preference as of September 30, 2025 and December 31, 2024, respectively | — | 52,847 |
| Stockholders’ equity (deficit): | ||
| Preferred stock, $0.00001 par value; 10,000,000 and zero shares authorized, zero shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively | — | — |
| Common stock, $0.00001 par value; 600,000,000 and 21,835,801 shares authorized, 26,652,775 and 4,234,798 shares issued, and 26,584,077 and 4,139,219 shares outstanding as of September 30, 2025 and December 31, 2024, respectively | — | — |
| Additional paid-in capital | 198,852 | 541 |
| Accumulated deficit | (92,192) | (71,171) |
| Total stockholders’ equity (deficit) | 106,660 | (70,630) |
| Total liabilities, convertible preferred stock, and stockholders’ equity (deficit) | $134,863 | $51,824 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.